Search clinical trials for: Telmisartan 40 mg

Total 10686 results

Yuhan Corporation

Completed

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Hypertension

Japan
Boehringer Ingelheim

Completed

Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism

Hypertension | Coronary Arteriosclerosis

Germany
Boehringer Ingelheim

Completed

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

Hypertension

Japan
George Medicines PTY Limited

Completed

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (GMRx2_ACT)

Hypertension

Australia, United States, United Kingdom, Poland, Sri Lanka, New Zealand, Czechia
Boehringer Ingelheim

Completed

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

Diabetic Nephropathies

Japan
Yuhan Corporation

Not yet recruiting

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

Hypertension

United States, Argentina, Brazil, Mexico, South Africa
Genencell Co. Ltd.

Recruiting

Efficacy and Safety of ES16001 in Patients With COVID-19

COVID-19

Korea, Republic of
Boehringer Ingelheim

Completed

Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)

Hypertension

Japan
Boehringer Ingelheim

Completed

A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension

Hypertension

Taiwan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Advanced Solid Tumor

United States
Grupo Español de Tumores Huérfanos e Infrecuentes
Astellas Pharma Inc; Apices Soluciones S.L.

Completed

Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study (GREKO III)

Ovarian Cancer

Spain
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Healthy

United States
Chong Kun Dang Pharmaceutical

Completed

CKD-828 Telmisartan Non-Responder Trial

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Open Label Study Telmisartan and Amlodipine in Hypertension

Hypertension

Belgium, Canada, Denmark, Finland, France, Korea, Republic of, Netherlands, Norway, Philippines, South Africa, Sweden, Taiwan
Zhongda Hospital
Sun Yat-sen University; Jiangsu Cancer Institute & Hospital; Zhejiang University and other collaborators

Not yet recruiting

A Real World Study of Regogfinib in HCC

Hepatocellular Carcinoma
Sandoz

Completed

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, Czechia, Australia, Austria, France, Germany, Hungary, Israel, Japan, Latvia, Lithuania, Poland, Portugal, Slovakia, Spain
Vigonvita Life Sciences

Completed

Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Healthy Subjects

China
AstraZeneca

Active, not recruiting

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)

Stage IB-IIIA Non-small Cell Lung Carcinoma

United States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
University of Bologna
Ipsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaborators

Unknown

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Non Small Cell Lung Cancer

Italy
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
Institute of Cancer Research, United Kingdom
AstraZeneca; Astellas Pharma Inc; Prostate Cancer UK

Terminated

Combination Study of AZD5069 and Enzalutamide. (ACE)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Healthy

Germany
UroGen Pharma Ltd.

Completed

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Neoplasms | Urologic Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms

India
MiMedx Group, Inc.
Rho, Inc.; NBCD A/S; United BioSource, LLC

Terminated

Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

Knee Osteoarthritis

United States
Istituto Oncologico Veneto IRCCS

Completed

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Glioblastoma Multiforme

Italy
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Sleep Apnea, Obstructive

United States
Abbott

Completed

Remission in Subjects With Crohn's Disease, 1 Year Phase (CLASSICII)

Crohn's Disease

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Cellulite

United States
Stealth BioTherapeutics Inc.

Completed

Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

Heart Failure

Netherlands, Italy, United Kingdom
Kirby Institute

Recruiting

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (TOPIC)

Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
ReAlta Life Sciences, Inc.

Withdrawn

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

COVID-19 | Acute Lung Injury | ALI

United States
Biocon Biologics Inc.
MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. Ltd

Completed

Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

Moderate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis

Bulgaria, Czechia, Estonia, Poland
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Malaria

Australia
JW Pharmaceutical

Recruiting

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients (EPIC)

Gout

Korea, Republic of
Future University in Egypt

Completed

Bioequivalence Study of Esomeprazole in Healthy Adult Subjects Under Fasting Condition

Bioequivalence

Egypt
Chong Kun Dang Pharmaceutical

Completed

The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy (TENUVA-BP)

Hypertension

Korea, Republic of
Kadmon Corporation, LLC
Quotient Sciences

Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Healthy Volunteers

United Kingdom
Boehringer Ingelheim

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Hepatitis C

Japan
Radboud University Medical Center
Astellas Pharma Europe B.V.

Completed

Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response (ILUMINATE)

Metastatic Castration Resistant Prostate Cancer

Netherlands
Reata, a wholly owned subsidiary of Biogen

Completed

A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults

Healthy

United States
ORIC Pharmaceuticals

Terminated

Study of ORIC-101 in Combination With Enzalutamide

Prostatic Neoplasms

United States
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Boehringer Ingelheim

Completed

Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5

Hypertension

France, Switzerland, Italy, Germany, Hong Kong, Netherlands, South Africa, Spain, Taiwan, Denmark, Sweden, Finland, Ireland, Korea, Republic of, Malaysia, Norway
Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
Akros Pharma Inc.

Completed

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Type II Hyperlipidemia

Netherlands
Bioprojet

Completed

Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

Parkinson's Disease | Excessive Daytime Sleepiness

France
CARE Pharma Shanghai Ltd.

Recruiting

A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH

Hemolysis | PNH

China

3

Subscribe